Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Lyon – page 85

1 185 clinical trials in Lyon, France across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Lyon at a glance
1 185
clinical trials
  • Research sites7
Type of trial
Recruitment status
Quick filters

1 185 trials in Lyon

Open in trial search

Malignant mast cell neoplasm

Not recruiting

Study of Entrectinib in Children and Adolescents with Advanced or Metastatic Solid Tumors or Primary CNS Tumors with No Satisfactory Treatment Options

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Entrectinib
  • Sponsor:F. Hoffmann-La Roche AG

Malignant melanoma+1

Not recruiting

Study Comparing Ipilimumab and Nivolumab with Standard Nivolumab for Patients with Stage III Melanoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Ipilimumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Asthma

Not recruiting

Study Comparing Depemokimab, Mepolizumab, and Benralizumab for Adults and Adolescents with Severe Eosinophilic Asthma

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Chronic myeloid leukaemia

Not recruiting

Study on the Tolerability and Efficacy of Asciminib vs. Nilotinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Novartis Pharma AG

Non-small cell lung cancer+4

Not recruiting

Study on the Effectiveness and Safety of Osimertinib for Patients with Stage IB-IIIA Non-Small Cell Lung Cancer After Tumor Removal

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AstraZeneca AB

Asthma

Not recruiting

Study on Benralizumab for Patients with Severe Asthma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Gastroenteropancreatic neuroendocrine tumour disease

Not recruiting

Study comparing 177Lu-edotreotide versus everolimus in patients with inoperable progressive neuroendocrine tumors of gastroenteric or pancreatic origin

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:ITM Solucin GmbH

Study on Melanoma Treatment: Comparing Encorafenib and Binimetinib with Ipilimumab and Nivolumab for Patients with BRAF V600 Mutation

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Squamous cell carcinoma of skin

Not recruiting

Study of Cemiplimab Compared to Placebo After Surgery and Radiation for Patients with High-Risk Skin Squamous Cell Carcinoma

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Malignant melanoma

Not recruiting

Study on the Effectiveness of Pembrolizumab and Lenvatinib for Patients with Resectable Mucosal Melanoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Institut Gustave Roussy

Neoplasm malignant+1

Not recruiting

Study of Entrectinib for Patients with Advanced or Metastatic Solid Tumors with Specific Gene Changes

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Entrectinib
  • Sponsor:F. Hoffmann-La Roche AG

Sickle cell disease

Not recruiting

Study on the Effectiveness of Decitabine and Tetrahydrouridine in Patients with Sickle Cell Disease Not Eligible for Hydroxyurea Treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Decitabine
  • Sponsor:Novo Nordisk A/S

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Lyon

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for endometrial carcinoma, bladder cancer, and various solid tumors. Current research explores combination therapies with novel immunotherapy approaches.

  • Triple-negative breast cancer treatments
  • Gastric and esophageal cancer therapies
  • Advanced pancreatic adenocarcinoma

Multiple studies are evaluating targeted therapies and immunological approaches for various tumor types.

02 Immunology and Infectious Diseases

Groundbreaking research in immune system modulation and infectious disease prevention, including studies on COVID-19 vaccines and immune response in critical conditions.

  • Novel COVID-19 intranasal vaccine development
  • Yellow fever vaccine studies
  • ICU-acquired immunosuppression treatment

Focus on developing innovative vaccination strategies and immune system interventions.

03 Chronic Conditions

Studies addressing long-term health conditions, with particular emphasis on kidney disease, cardiovascular health, and metabolic disorders.

  • Chronic kidney disease management
  • Heart failure prevention
  • Hypertriglyceridemia treatment

Innovative approaches combining established and experimental treatments for improved patient outcomes.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.